Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
NCT02476955 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · PHASE1 · terminated · last registry update 2020-09-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-08-11Also stopped (terminated): Novartis Pharmaceuticals, Afuresertib (NCT02177682)
- 2021-08-10Results posted on the registry: National Cancer Institute (NCI), Capivasertib (NCT04439123)
- 2021-04-28Phase 3 first posted: AstraZeneca, Capivasertib + Fulvestrant (NCT04862663)
- 2021-04-20Phase 3 first posted: Laekna Limited, Afuresertib + Afuresertib/placebo (NCT04851613)
- 2021-01-11Results posted on the registry: Genentech, Inc., Ipatasertib + Paclitaxel (NCT02162719)
- 2020-12-02Phase 3 first posted: Canadian Cancer Trials Group, Ipatasertib + Fulvestrant (NCT04650581)
- 2020-10-14Results posted on the registry: National Cancer Institute (NCI), Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide (NCT01902173)
- 2020-10-06Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Ipatasertib + Paclitaxel (NCT04561817)
- 2020-09-24Also stopped (terminated): Prescient Therapeutics, Ltd., Triciribine + Carboplatin (NCT01690468)
- 2020-09-24Also stopped (terminated): Prescient Therapeutics, Ltd., Cyclophosphamide + Doxorubicin Hydrochloride (NCT01697293)
- 2020-07-30Phase 3 first posted: AstraZeneca, Capivasertib + Abiraterone Acetate (NCT04493853)
- 2020-03-12Phase 3 first posted: AstraZeneca, Fulvestrant + Capivasertib (NCT04305496)
- 2020-02-24Results posted on the registry: National Cancer Institute (NCI), Trametinib + Uprosertib (NCT01979523)
- 2019-12-05Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Bicalutamide (NCT01251861)
- 2019-11-26Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Ipatasertib (NCT04177108)
- 2019-11-12Results posted on the registry: Merck Sharp & Dohme LLC, MK-2206 + docetaxel (NCT00848718)
- 2019-10-10Also stopped (terminated): National Cancer Institute (NCI), Akt Inhibitor MK2206 + Everolimus (NCT01239342)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision